Clinical Trial: A Multicenter Trial of YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer

U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07390565) titled 'A Multicenter Trial of YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer' on Jan. 22.

Brief Summary: Globally, lung cancer stands as the foremost cause of cancer-related mortality. Among its subtypes, small cell lung cancer (SCLC) represents an exceptionally aggressive malignancy, accounting for approximately 15-20% of all lung cancer cases. Over two-thirds of SCLC patients are diagnosed at an extensive stage, facing a median survival of only 7-12 months, a 2-year survival rate below 5%, and a dismal 5-year survival rate of 2%, underscoring its poor prognosis and high mortality. First-line treatment f...